Steven Woloshin, MD
Title(s)
Professor of Health Policy and Clinical Practice
Professor of Medicine
Professor of Community and Family Medicine
Department(s)
Health Policy and Clinical Practice
Medicine
Community and Family Medicine
Education
Dartmouth Medical School, MS 1996
Boston University School of Medicine, MD 1987
Boston University, BA 1987
Programs
The Dartmouth Institute for Health Policy and Clinical Practice
Contact Information
Dartmouth Medical School
HB 7900
Hanover NH 03755
Phone: 603 646 5672
Email: steven.woloshin@dartmouth.edu
Professional Interests
Dr. Woloshin's research interest is in learning how to enhance the quality of medical communication to the public, patients, physicians and policymakers. His work (in collaboration with Dr. Lisa Schwartz) has 2 main approaches: improving the quality of messages presenting health information to people, and preparing audiences to make sense of the messages they receive. His main focus is on the communication of medical statistics and information about the benefits and harms of screening and prescription drugs.
Communicating Drug Safety and Safe Use Conditions in Risk Evaluation and Mitigation Strategy Materials. Whole-body magnetic resonance imaging (MRI) or computed tomography (CT) screening for reducing morbidity and mortality from multiple diseases in asymptomatic adults. Navigating the Prescription Drug Information System. Patient- and Physician-Identified Considerations for Clinical Implementation of a New Risk-Based Prediction Tool to Guide Surveillance Mammography in Breast Cancer Survivors. Prescription Drug Promotion by Social Media Influencers: A Systematic Scoping Review. Physician Perspectives on Real-World Evidence for Prescribing to Older Patients. Responding to public health challenges of medical advice from social media influencers. Patient and Physician Perspectives on Using Risk Prediction to Support Breast Cancer Surveillance Decision Making. Less is more for patients, practitioners, public and planet: a taxonomy for the harms of too much medicine. Reporting of Clinical Trial Uncertainties With New Cancer Drugs in Journal Publications and Clinical Guidelines. |
|